News for Kura Oncology, Inc. (KURA)

**media[560114]**

Kura Oncology's (KURA) ziftomenib shows AML promise amid competition. See why I'm inclined to view the current price levels as a tentatively optimistic buy-in point.

Kura Oncology, Inc. (NASDAQ:KURA) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ETCompany ParticipantsPatti Bank - IRTroy Wilson - President...

Collaboration Revenue: $53.9 million for Q4 2024, compared to none for Q4 2023.Research and Development Expenses: $52.3 million for Q4 2024, up from $32.5 mill

The following slide deck was published by Kura Oncology, Inc.

Kura Oncology (KURA) delivered earnings and revenue surprises of 65.08% and 76.49%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Revenue: $53.9 million for Q4 2024, surpassing the estimated $8.50 million.Net Loss: $19.2 million for Q4 2024, a significant improvement from a $42.8 million

”“ KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint ”“ ”“ Alignment reached with FDA and EMA on key aspects of the KOMET-017

**media[551505]**

SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the ”œCompany”) ( KURA), a clinical-stage biopharmaceutical company committed to realizin

On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio) made a significant move by acquiring an additional 3,142,000 shares of Kura Oncology Inc. This

On February 5, 2025, Suvretta Capital Management, LLC made a significant move by acquiring additional shares in PepGen Inc (PEPG). The firm added 486,611 shares

On December 31, 2024, Suvretta Capital Management, LLC executed a significant transaction involving PepGen Inc (PEPG), reducing its holdings by 486,611 shares.

SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the ”œCompany”) ( KURA), a clinical-stage biopharmaceutical company committed to realizin

Syndax Pharma (SNDX) stock rose after Kura Oncology (KURA) posted a mid-stage trial win for a leukemia drug is similar to former's lead drug. Read more here.

Pennsylvania-based Lipella Pharmaceuticals Inc. (LIPO), a clinical-stage biotechnology company is up over 180 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Kura Oncology (KURA) stock slid 7% in post-market trading after the company issued an update on its drug ziftomenib.

**media[533438,533439]**

Kura Oncology's stock plummeted 50% after announcing a collaboration with Kyowa Kirin, making it a less attractive acquisition target despite its promising AML drug candidate ziftomenib.